Clinical data
AHFS/Drugs.com International Drug Names
ATC code M05BX01 (WHO)
Synonyms 3-phenyl-7-propan-2-yloxychromen-4-one
CAS Number 35212-22-7 N
PubChem (CID) 3747
ChemSpider 3616 N
KEGG D01338 YesY
ECHA InfoCard 100.125.854
Chemical and physical data
Formula C18H16O3
Molar mass 280.318 g/mol
3D model (Jmol) Interactive image
 NYesY (what is this?)  (verify)

Ipriflavone is a synthetic isoflavone which may be used to inhibit bone resorption,[1] maintain bone density and to prevent osteoporosis in postmenopausal women. It is not used to treat osteoporosis. It slows down the action of the osteoclasts (bone-eroding cells), possibly allowing the osteoblasts (bone-building cells) to build up bone mass.

A clinical trial reported in 2001 that it was not effective in prevention or treatment of osteoporosis.[2]

A double-blind study reveals that ipriflavone might be effective on reducing tinnitus on otosclerosis sufferers.[3]


  1. Civitelli, R. (1997). "In Vitro and in Vivo effects of ipriflavone on bone formation and bone biomechanics". Calcified Tissue International. 61: S12–4. doi:10.1007/s002239900378. PMID 9263610.
  2. Alexandersen, P.; Toussaint, A; Christiansen, C; Devogelaer, JP; Roux, C; Fechtenbaum, J; Gennari, C; Reginster, JY; Ipriflavone Multicenter European Fracture Study (2001). "Ipriflavone in the Treatment of Postmenopausal Osteoporosis: A Randomized Controlled Trial". JAMA. 285 (11): 1482–8. doi:10.1001/jama.285.11.1482. PMID 11255425.
  3. Sziklai, I; Komora, V; Ribári, O (1992). "Double-blind study on the effectiveness of a bioflavonoid in the control of tinnitus in otosclerosis". Acta chirurgica Hungarica. 33 (1–2): 101–7. PMID 1343452.

This article is issued from Wikipedia - version of the 4/2/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.